Moderna launches first human trial of EBV mRNA vaccine
NCT ID NCT07478952
First seen Mar 19, 2026 · Last updated May 01, 2026 · Updated 5 times
Summary
This early-stage study is testing an experimental mRNA vaccine called mRNA-1189 to see if it is safe and can trigger an immune response against Epstein-Barr virus (EBV). The trial involves 120 healthy adults aged 18 to 30. Researchers will compare two ways of giving the vaccine: a shot into the skin or into the muscle.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPSTEIN-BARR VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Doherty Clinical Trials
NOT_YET_RECRUITINGMelbourne, Victoria, VIC 3149, Australia
-
Nucleus Network
RECRUITINGMelbourne, Victoria, VIC 3004, Australia
Conditions
Explore the condition pages connected to this study.